摘要
非酒精性脂肪肝(NAFLD)不仅由于其患病率上升,更因为其缺乏可持续的治疗方案而成为是巨大的难题。肠道菌群被认为参与其发生和发展过程,因此,他们的控制作用被当作治疗目标研究。本文综述了肠道菌群对NAFLD发病机制的参与情况。此外,我们总结了旨在治疗NAFLD患者肠道微生态失调的最新的动物和人体实验研究结果。最后,我们综述了在治疗NAFLD时控制短链脂肪酸和胆汁酸信号的疗效的证据。
关键词: 胆汁酸,菌群失调,脂肪肝,肠道菌群,NAFLD,NASH。
图形摘要
Current Drug Targets
Title:Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
Volume: 16 Issue: 12
Author(s): Marialena Mouzaki and Robert Bandsma
Affiliation:
关键词: 胆汁酸,菌群失调,脂肪肝,肠道菌群,NAFLD,NASH。
摘要: Non-alcoholic fatty liver disease (NAFLD) is a challenge not only due to its rising prevalence but also, and perhaps more importantly, due to the lack of sustainable treatment options. Intestinal microbiota are thought to participate in the development and progression of NAFLD and their manipulation is, hence, being investigated as a treatment aim. This review summarizes the involvement of intestinal microbiota in the pathogenesis on NAFLD. In addition, we synthesize the results of the most recent animal and human studies aimed at treating dysbiosis seen in patients with NAFLD. Lastly, we review the evidence regarding the efficacy of manipulating short chain fatty acid and bile acid signaling in the treatment of NAFLD.
Export Options
About this article
Cite this article as:
Marialena Mouzaki and Robert Bandsma , Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease, Current Drug Targets 2015; 16 (12) . https://dx.doi.org/10.2174/1389450116666150416120351
DOI https://dx.doi.org/10.2174/1389450116666150416120351 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma
Protein & Peptide Letters Bowel Habit in Preterm New borns: Effect of New Formulas
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Alterations in Renal and Prostate Cancer
Current Drug Metabolism GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Matrix Metalloproteinases in Cancer Metastasis: Molecular Targets for Prostate Cancer Prevention by Green Tea Polyphenols and Grape Seed Proanthocyanidins
Endocrine, Metabolic & Immune Disorders - Drug Targets How to Overcome Diabetic Retinopathy: Focusing on Blood-Retinal Barrier
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Her2/neu Small Interfering RNA Delivered in Culture by a Streptavidin Nanoparticle
Current Drug Delivery Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment
Combinatorial Chemistry & High Throughput Screening